Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Strategic Asset Allocation Index
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd strategic asset allocation index. Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) has a Strategic Asset Allocation Index of 58.5% as of September 2023. Strategic assets (PP&E of CN¥402.17 Million plus long-term investments of CN¥-) total CN¥402.17 Million, measured against net assets of CN¥687.58 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check 300534 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2012–2021)
Strategic asset allocation index of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2012 to 2021. This chart shows how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's Strategic Asset Allocation Index has evolved across 10 annual periods from 2012 to 2021. As of September 2023, the index stands at 58.5%, representing strategic assets of CN¥402.17 Million against net assets of CN¥687.58 Million CNY.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Strategic Asset Allocation Index by Year (2012–2021)
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd strategic asset allocation index by year from 2012 to 2021. The table below presents the year-by-year Strategic Asset Allocation Index for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2012 to 2021, covering 10 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300534 market cap overview.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 41.6% | CN¥305.21 Million | CN¥305.21 Million | CN¥- | CN¥732.84 Million | ▼ -2.6 pp |
| 2020 | 44.2% | CN¥326.76 Million | CN¥326.76 Million | CN¥- | CN¥739.13 Million | ▲ +1.8 pp |
| 2019 | 42.4% | CN¥312.98 Million | CN¥312.98 Million | CN¥- | CN¥738.88 Million | ▼ -8.2 pp |
| 2018 | 50.6% | CN¥364.58 Million | CN¥310.38 Million | CN¥54.20 Million | CN¥720.83 Million | ▼ -10.8 pp |
| 2017 | 61.3% | CN¥436.90 Million | CN¥382.70 Million | CN¥54.20 Million | CN¥712.19 Million | ▲ +4.0 pp |
| 2016 | 57.4% | CN¥403.87 Million | CN¥349.67 Million | CN¥54.20 Million | CN¥703.74 Million | ▼ -30.7 pp |
| 2015 | 88.1% | CN¥357.21 Million | CN¥355.21 Million | CN¥2.00 Million | CN¥405.57 Million | ▲ +46.7 pp |
| 2014 | 41.4% | CN¥150.25 Million | CN¥150.25 Million | CN¥- | CN¥363.10 Million | ▲ +14.4 pp |
| 2013 | 27.0% | CN¥86.10 Million | CN¥86.10 Million | CN¥- | CN¥318.92 Million | ▲ +9.5 pp |
| 2012 | 17.5% | CN¥30.08 Million | CN¥30.08 Million | CN¥- | CN¥171.46 Million | — |